Robert Nelsen insider trades

Open-market stock purchases and sales by Robert Nelsen, Director, 10% Owner at Prime Medicine, Inc, from SEC Form 4 filings since Jun 2, 2010.

Track record: 0% of 7 scored buys are up 5% or more since purchase, averaging -46%.

Recent trades

DateStockTradeValue
Jun 5, 2026PRME Prime Medicine, IncBought (not open market)—
Jun 4, 2026SANA Sana Biotechnology, IncBought (not open market)—

Companies traded

  • PRME Prime Medicine, Inc: 3 buys, last Jun 5, 2026
  • SANA Sana Biotechnology, Inc: 2 buys, last Jun 4, 2026
  • LYEL Lyell Immunopharma, Inc: other filings, last Jun 14, 2024
  • VIR Vir Biotechnology, Inc: 1 buy, last May 30, 2024
  • DNLI Denali Therapeutics Inc: other filings, last Jun 2, 2021
  • KRTX Karuna Therapeutics, Inc: 1 buy, last Apr 13, 2021
  • BEAM Beam Therapeutics Inc: other filings, last Mar 31, 2021
  • UBX Unity Biotechnology, Inc: other filings, last Jun 18, 2020
  • DNI Denali Therapeutics Inc: other filings, last Aug 8, 2019
  • SNNA Sienna Biopharmaceuticals, Inc: other filings, last Jun 1, 2018
  • JUNO Juno Therapeutics, Inc: other filings, last Mar 5, 2018
  • SYRS Syros Pharmaceuticals, Inc: 1 buy, last Jun 8, 2017

Get free alerts when Robert Nelsen files a new trade →